A single‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma

Abstract Background MCD (MYD88L265P/CD79Bmut) diffuse large B‐cell lymphoma has a poor prognosis. There is no published clinical research conclusion regarding zanubrutinib or orelabrutinib for the initial treatment of MCD DLBCL. Aims This study aimed to analyse the efficacy and safety of Bruton'...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Ting Deng, Shiyuan Zhang, Min Xiao, Jia Gu, Liang Huang, Xiaoxi Zhou
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Subjects:	Bruton's tyrosine kinase inhibitor CD79Bmut diffuse large B‐cell lymphoma MCD subtype MYD88mut
Online Access:	https://doi.org/10.1002/cam4.7005